This time Wei Kang issued the announcement. He said that the company's new drug research and development has achieved a virtuous cycle and there is no shortage of money for the time being.
On the contrary, the next goal is to spend more money, especially R&D investment. Sanqing still has a clear gap with international pharmaceutical giants in this area. The short-term goal is to catch up, and the long-term goal is to strive to far surpass its peers.
At the same time, Sanqing Group’s pharmaceutical business will never be listed.
As soon as the news came out, major netizens immediately laughed.
"Mr. Wei is awesome, a man who can't get enough capital."
"I'm really happy to see the capital shrinking."
"The next goal is to spend more money to equal Pfizer, right? I laughed so hard."
"That's right. Pharmaceutical companies should serve the people and meet social needs. How can they be controlled by capitalists?"
"If we don't go public, we won't be controlled by capital, and we won't sell high-priced drugs. Now we are relieved."
"Foreign pharmaceutical giants invest tens of billions of dollars a year in R&D. I think President Health's spending plan may be a bit difficult."
"It's not difficult, it's not difficult. If you give each person in the country one hundred yuan, you can easily achieve your goal, hahaha."
"Don't you see what Mr. Wei means? This is the rhythm of one person driving a city. Kunming City is going to be developed, and housing prices are expected to soar!"
"I can tell that they are probably going to recruit people again. Hey, I'm about to graduate and I'm going to send in my resume."
"I envy the academics above. If I could go back in time, I would have chosen biochemistry as my major."
"If nothing else, if Sanqing's R&D investment is as high as Juwei's, it can support the entire domestic pharmaceutical industry."
"Yeah, you don't know. The total R&D investment of domestic pharmaceutical companies is not as much as that of a foreign giant. And the R&D investment of foreign pharmaceutical giants is not as good as that of Juwei. Juwei's R&D investment ranks first in the world. three."
"Hey, it's so scary. Is Sanqing going to become the domestic R&D double champion with Juwei?"
"Thirty years have passed since Hedong, and thirty years have passed since Hexi. Feng shui has changed. This year we are going to the pharmaceutical industry. Our biochemistry, environmental materials, and materials industry should prosper!"
Not to mention the excitement of netizens and the eagerness of the financial circle, the CEOs of domestic pharmaceutical companies couldn't help but blush when they saw Sanqing's statement, and turned their heads one after another, pretending they couldn't see it.
"The national situation is such that there is nothing we can do." They thought.
A person's inertia is often terrifyingly stubborn, let alone the inertia of an industry.
Although Sanqing is working hard to buck the trend, it is not yet time to reverse the situation of the entire industry.
Just when people in the industry remained silent on this statement, a post suddenly appeared on the Internet: "Discussing the surprising impact of my country's pharmaceutical industry's R&D investment from the statement of Sanqing!"
The poster is Chang Sanwei, director of the Department of Biology at Peking University, a well-known biological scientist, and an academician of the Academy of Sciences. This person has an outstanding reputation online and is known for being outspoken and outspoken. He often speaks angrily against unfair or bizarre current situations in various industries, so he is nicknamed Often criticized.
The post provided a detailed analysis of the R&D investment of major domestic pharmaceutical companies and praised Sanqing's emphasis on R&D, which immediately sparked heated discussions across the entire network.
"At this moment, a phenomenon that can be called 'Chinese surprise' has occurred in the domestic pharmaceutical industry."
"The pharmaceutical company that is the most profitable in the industry and has the largest revenue does not go public or raise funds. It silently spends all the money it earns on drug research and development and basic scientific research. One company supports an industry."
“But listed pharmaceutical companies are insisting on following a path full of Chinese characteristics.
Data shows that the total R&D expenses of the 373 listed pharmaceutical companies last year were only 61.3 billion yuan, which was less than that of the multinational pharmaceutical company Roche.
Take Hengrui, a leading pharmaceutical company, as an example. Last year, the company ranked outside the 40th largest pharmaceutical company in the world in terms of R&D expenditures. If all sales expenses are spent on R&D, the total R&D expenses will be approximately US$1.9 billion, and the ranking will be significantly improved to around 20, which can be on par with medium-sized pharmaceutical companies such as Novo Nordisk.
Domestic pharmaceutical companies have made a lot of money in the past two years. Where did they spend their money?
The answer is marketing promotion.
Last year, a total of 373 listed companies released performance reports, with total revenue of 1.92 trillion yuan and net profit of 135.1 billion yuan. Sales expenses are as high as 279 billion yuan, of which 67.2 billion yuan is sales employee salaries, and the remaining 211.8 billion yuan is mainly used for promotion, including academic promotion, entertainment expenses, conference fees, publicity expenses, travel expenses, etc.
Take Hengrui Pharmaceutical as an example. Last year, the company's total revenue was 27.7 billion yuan and net profit was 6.3 billion yuan. The annual sales expenses were 9.8 billion yuan, of which 4.2 billion yuan was spent on academic promotion, construction of innovative drug professional platform and other market expenses.
You get what you put in, and with such a low investment, the entire industry is naturally full of bubbles. Although the ppts of various innovative drug companies are full of hype, in fact, 90% of domestic new drug projects are derivative new drugs developed for targets that have been verified at home and abroad.
Although derivative drugs imitate the original drug but slightly change the chemical structure of the original drug, they are all derivative drugs in a strict sense.
Foreign new drugs are all original new drugs, which are the first or best in their class. The development cost of new drugs is 1 billion to 2.2 billion US dollars. The success rate from entering clinical to obtaining new drug approval is 9.6%, while the development cost of domestic derived new drugs is less than 100 million US dollars. US dollars, the success rate from clinical trials to obtaining new drug approval is as high as 80%.
This copycat-style new drug strategy looks beautiful, but it also means reduced profit prospects and intensified business competition.
So, are there any bright spots in my country's pharmaceutical industry that can lead it in the world?
This, of course.
That is - valuation, absolutely the best in the world.
From the perspective of market size, the current size of my country's pharmaceutical market is about 800 billion yuan, which is about 4 times that of my country. The world's pharmaceutical market has reached 1.2 trillion US dollars, which is about 9 times that of my country.
From the perspective of corporate strength, those foreign pharmaceutical companies that have the latest and best truly new pharmaceutical products of their kind have high R&D investments and high revenue and profits, but their market value is lower than that of a domestic pharmaceutical company that only has derivative products for the domestic market.
Doesn't this make people feel funny and ridiculous?
Isn't this China's surprise?
Haha, it can be said that the current domestic new drug companies are just trying to sell cabbage, and they are selling at valuations of 0.0 cents.
In any case, blacksmithing requires one's own hard work. If you want to produce results, you not only need hard power, but also real financial investment in scientific research.
This industry needs to be like Sanqing, calm down and cultivate deep internal skills in order to keep up with the pace of the leaders and not fall behind or fall behind. Otherwise, I am afraid that what will usher in will be a brutal purge and reshuffle. After the market competition, there will be nothing but chicken feathers. How many companies will be able to survive? "
Netizens exclaimed and sighed after watching it.
"Sanqing is indeed a breath of fresh air in the industry."
"This is definitely an insider who can see clearly. Reform of this industry is imperative."
"To be honest, I would rather only have one Sanqing company left in the entire industry, rather than spend money to take medicines from these waste pharmaceutical companies."
"I see, I finally understand how all the weird phenomena in the pharmaceutical industry come about."
"No wonder the price of medicines is getting higher and higher, but really effective medicines still have to be imported. It turns out that they are all used by these grandsons for marketing."
"Oh my god, I'm afraid I'm going to offend a lot of people now."
"Everyone is already an academician, so there is nothing to be afraid of. Our country needs experts like this to speak out in order to urge the industry to move forward."
"This is a real expert. It's really cool to argue. I love it."
"I hope Sanqing can play a leading role in the industry, even if it allows other pharmaceutical companies to follow suit."
"I find it difficult. If you earn a lot of fast money, can you still earn the hard money of research and development, which is slow and difficult?"
This message also reached Wei Kang's ears. He watched it carefully and sighed: "No one knows me better than you."
This post simply spoke to his heart, and the other party also praised Sanqing highly.
That must show support.
Wei Kang acted quickly and immediately contacted Academician Chang through Academician Qi and invited him to become the honorary consultant of Sanqing.
The two sides hit it off immediately, and Sanqing took advantage of the situation and proposed to carry out strategic cooperation between schools and enterprises with the Department of Biology and Chemistry of Peking University.
Sanqing is now rich and famous, but what it lacks most is cutting-edge scientific research capabilities and outstanding industry talents.
Wei Kang looked at the talents from Beijing University with great envy. In the past, these people had to go abroad to study, and most of them would never come back.
Now that Sanqing has gained a reputation among pharmaceutical companies around the world, its attraction to these high-level talents will surely increase dramatically.
After all, who doesn’t want to return home after completing their studies and returning home in fine clothes?
In the past, there were no pharmaceutical companies in China that were willing to spend money on scientific research. Now, there are Sanqing.
I believe there will be a big wave of overseas talent returning.
And Sanqing also wants to build the world's number one biochemical R&D base.
